Overview
ALPHAMAB-B (9966)
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment...
- Open
- 5.545
- High
- 5.670
- Low
- 5.280
- Prev. Close
- 5.745
- Volume
- 1.22M
- Turnover
- 6.69M
- Avg Price
- 5.473
- Bid/Ask Ratio
- -14.29%
- Amplitude
- 6.79%
- 52wk High
- 12.200
- Volume Ratio
- 0.78
- Turnover Ratio
- 0.13%
- 52wk Low
- 5.280
- HK Mkt Cap
- 5.46B
- Market CapHKD
- 5.46B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.210
- EPSDynamic
- -0.0965
- EPSStatic
- --
- BVPS
- 2.00
- P/B
- 2.84
- HK Shares
- 965.15M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 965.15M
- Min lot size
- 1,000
- Currency
- HKD
ALPHAMAB-B Analyst Rating
View moreForecast & Rating
Oct 12, 2026- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Alphamab Oncology (9966.HK) reversed early losses to close at HK$5.635, down 1.91%, after sliding to HK$5.285 intraday, a fresh 52-week low, as a confirmed death cross and follow-through selling from the prior day's trough pushed the morning session from the HK$5.745 open to the day's low within half an hour, before afternoon buying recovered most of the gap on 1.22 million shares worth HK$6.69 million. Fundamentals offer little offset: Q2 2026 revenue fell 10.5% year on year to HK$156.6 million, the net loss widened nearly threefold to HK$23.37 million and EPS was -HK$0.0242. The stock is down 40.92% year to date, 53.6% below its 19 April peak of HK$12.20, and trades under both its MA20 of HK$6.37 and MA60 of HK$7.52. Offsetting items include new CFO David Ng, repeated buybacks and FDA clearance of JSKN021 for trials. Though a 2.84x price-to-book against negative earnings shows profitability has yet to turn.
- Nov, 12
Alphamab Oncology (9966.HK) reversed an early rise and fell as much as 6.4% intraday before paring losses, closing at HK$6.000, down 2.44% from HK$6.150, after Q2 2026 revenue fell 10.5% year on year to HK$156.6 million and net loss widened 297.68% to HK$23.4 million. The stock touched HK$6.190 at 09:35 BJ, then slid to HK$5.755 at 14:31 BJ, a fresh 52-week low, before afternoon buying lifted it back toward the open. Net margin was -14.9% and EPS -HK$0.0242, alongside PE -28.58, PB 3.01 and a HK$5.79 billion market value; the price sits below MA20 (6.477) and MA60 (7.602), is down 37.37% year to date and 50.82% below the 52-week high of HK$12.20, with 955,000 shares and HK$5.66 million turnover. Though repeated share buyback disclosures, FDA clearance for a JSKN021 Phase I trial, first-patient dosing in the JSKN033 Phase III cervical cancer study and the appointment of David Ng as CFO offered some support into the close.
- Nov, 9
Alphamab Oncology (9966.HK) closed up 1.36% at HK$6.34 after a spike-and-fade session: it touched HK$6.60 at 09:54 BJ before sliding to HK$6.28 by 13:12 BJ, with only 558,000 shares and HK$3.58 million traded (0.06% turnover) and a HK$6.418 average price above the close. The company remains loss-making: Q2 2026 revenue of HK$156.6 million fell 10.5% yoy, the net loss widened 297.7% yoy to HK$23.4 million, net margin stood at -14.92%, EPS at -HK$0.0242 and PB at 3.18x. The stock is down 33.82% YTD and 48.03% below its 19 April 52-week high of HK$12.20, though still 8.01% above the 2 November low of HK$5.87, while trading below both MA20 of HK$6.619 and MA60 of HK$7.706. Liquidity is thin, so the intraday swing reflects sparse flow more than conviction.
- Nov, 6
Shares reversed early strength: the stock opened at HK$6.660, the session high, then slid to HK$6.215 by 13:25 BJ and closed at HK$6.255, down 6.01% on HK$5.07 million turnover, unwinding the roughly 7% rally booked after the FDA cleared JSKN021 for a Phase I trial. The move sat against a still-lossmaking profile, with Q2 revenue of HK$156.6 million down 10.5% year on year and a net loss of HK$23.37 million. Buybacks of 446,000 shares for about HK$2.74 million between November 2 and 5, first-patient dosing in JSKN033's Phase III cervical cancer study, and ESMO presentations covering KN026 and JSKN003 did not stem the decline. At HK$6.255 the stock trades below its 20-day MA of HK$6.67 and 60-day MA of HK$7.742, is down 34.71% year to date and 48.73% below the 52-week high of HK$12.20, and sits just 6.56% above the HK$5.87 low, with market capitalization of HK$6.04 billion on a 3.14 price-to-book. Though the ADC pipeline continues to advance.
- Nov, 4
FDA clearance of an IND for JSKN021 brought in buyers, and Alphamab Oncology (9966.HK) traced a dip-and-rebound session: it slid to HK$6.120 in the morning, then pushed to HK$6.600 at 14:09 BJ before closing at HK$6.545, about 6.9% above the intraday low on 1.064 million shares. The news flow has been dense: buybacks of 230,000 and 160,000 shares on 2 and 3 November, a first patient dosed in the Phase III cervical cancer trial of JSKN033, and ESMO 2026 disclosures of JSKN003 plus two Phase III KN026 (anbenitamab) datasets as LBA oral presentations, including a 54% reduction in risk of progression or death in Phase III breast cancer. Though Q2 2026 revenue of HK$156.6 million was down 10.5% year on year, with a net loss of HK$23.37 million and a -14.9% net margin and PE at -31.2, the stock still trades below its MA20 of HK$6.806 and MA60 of HK$7.81, down 31.68% year to date and 46.92% below the 52-week high of HK$12.33, only 11.5% above the 2 November low of HK$5.87.
News
PUBT · Alphamab Oncology Discloses Share Repurchase in HKEX Next Day Return
Market Movers · 康宁杰瑞制药-B 创 52 周新低,现报 $5.54,现跌约 3%。
Market Movers · Alphamab hits 52-week low in Hong Kong trading
Market Movers · Alphamab falls 6% in Hong Kong trading
PUBT · Alphamab Oncology Appoints David Ng as Chief Financial Officer
PUBT · Alphamab Oncology Files Next Day Disclosure Return With HKEX Announcing Share Buyback
